B.S., 1992, University of Alberta, Edmonton, Alberta, Canada
Regulation of small intestinal function by various nutrients and gastrointestinal-specific peptides.
Dr. Tappenden's research program is directed at achieving a greater understanding of the regulation of small intestinal function by various nutrients and gastrointestinal-specific peptides. Through the use of preclinical animal models simulating necrotizing enterocolitis, short bowel syndrome, diarrheal diseases (Salmonella typhimurium), and specialized nutrition support (enteral and parenteral nutrition) structural and functional adaptation of the intestine are explored. A necrotizing enterocolitis (NEC) neonatal piglet model is used to examine cellular mechanisms and regulation of nutrient processing within the compromised intestine. As many patients who develop NEC currently undergo intestinal resection, resulting in a condition known as short bowel syndrome (SBS), the lab also focuses on understanding the mechanisms whereby short-chain fatty acids, the products of dietary fiber fermentation, modulate intestinal adaptation during short bowel syndrome. Other scientific contributions include the identification of cellular and functional markers of intestinal adaptation that can be used to assess the efficacy of therapeutic strategies for humans with SBS. Ultimately, these research efforts will optimize the quality of life for individuals with intestinal failure.
Commare, C.E. and K.A. Tappenden. (2007) Development of the infant intestine: Implications for nutrition support. Nutrition in Clinical Practice 22(2):159-173.
Tappenden, K.A. and A.S. Deutsch. (2007) The physiological relevance of the intestinal microbiota - Contributions to human health. Journal of the American College of Nutrition 26(6):679S-683S.
Thymann, T., D.G. Burrin, K.A. Tappenden, C.R. Bjornvad, S.K. Jensen, P.T. Sangild. (2006) Formula-feeding reduces lactose digestive capacity in neonatal pigs. British Journal of Nutrition 95(6):1075-1081.
Jeppesen, P.B., E.L. Sanguinetti, A. Buchman, L. Howard, J.S. Scolapio, T.R. Ziegler, J. Gregory, K.A. Tappenden, J. Holst, and P.B. Mortensen. (2005) Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut 54(9):1224-1231.